Drug Trial Radar · NCT06176508
Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis
Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
160
Planned (sponsor's estimate)
Start
Feb 26, 2024
Primary completion
Apr 28, 2026
Study completion Aug 28, 2026
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Dec 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.
Conditions
- Psoriatic Arthritis
Interventions
HS-10374Drug
Administered orally QD for 16 weeks
HS-10374-matched placebo tabletsDrug
Administered orally QD for 16 weeks
Tofacitinib 5Mg Tab,OralDrug
Administered orally BID for 16 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants meeting American College of Rheumatology improvement of 20% (ACR20) response at Week 16Time frame: At week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.